Literature DB >> 12766692

Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.

Elizabeth A Hembree1, David S Riggs, Michael J Kozak, Martin E Franklin, Edna B Foa.   

Abstract

What is the long-term outcome of patients with obsessive-compulsive disorder (OCD) who are treated with exposure and response (ritual) prevention (EX/RP) alone, serotonergic medications alone, or their combination? How is the long-term outcome of these patients affected by the discontinuation? Follow-up assessments were conducted with 62 patients treated for OCD an average of 17 months posttreatment (range: 6-43 months). Patients received one of three treatments: serotonergic medications (fluvoxamine or clomipramine), intensive behavior therapy involving EX/RP, or intensive EX/RP with concurrent antidepressant medication. At follow-up, no differences in OCD symptom severity were found among the three treatment groups. However, when current medication use was taken into consideration, differences among the three treatment groups emerged. Among patients who were medication-free at the time of follow-up assessment (n=37), those in the EX/RP-alone and EX/RP-with-medication groups had lower symptom severity ratings than those in the medication-only group on 4 out of 6 measures. There were no differences in OCD severity ratings among patients taking medications at follow-up (n=25). Although these findings are interpreted with caution due to the uncontrolled nature of the study, results suggested that long-term outcome may be superior following EX/RP than following serotonergic medications, after discontinuation. For patients who remain on medications, the treatment produced benefits equivalent to EX/RP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766692     DOI: 10.1017/s1092852900018629

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  8 in total

1.  Clinical treatment of obsessive compulsive disorder.

Authors:  Christopher Pittenger; Ben Kelmendi; Michael Bloch; John H Krystal; Vladimir Coric
Journal:  Psychiatry (Edgmont)       Date:  2005-11

2.  A solid majority remit following evidence-based OCD treatments: a 3-year naturalistic outcome study in pediatric OCD.

Authors:  Karin Melin; Gudmundur Skarphedinsson; Ingela Skärsäter; Bente Storm Mowatt Haugland; Tord Ivarsson
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-03-03       Impact factor: 4.785

3.  Psychopharmacology of tic disorders.

Authors:  Myriam Srour; Paul Lespérance; Francois Richer; Sylvain Chouinard
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2008-08

4.  Current diagnosis and treatment of anxiety disorders.

Authors:  Alexander Bystritsky; Sahib S Khalsa; Michael E Cameron; Jason Schiffman
Journal:  P T       Date:  2013-01

Review 5.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01

6.  A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Deborah Roth Ledley; Jonathan D Huppert; Shawn Cahill; Donna Vermes; Andrew B Schmidt; Elizabeth Hembree; Martin Franklin; Raphael Campeas; Chang-Gyu Hahn; Eva Petkova
Journal:  Am J Psychiatry       Date:  2008-03-03       Impact factor: 18.112

Review 7.  Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).

Authors:  G M Soomro; D Altman; S Rajagopal; M Oakley-Browne
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

8.  Effectiveness of Rajyoga meditation as an adjunct to first-line treatment in patients with obsessive compulsive disorder.

Authors:  Kiran Mehta; Shivangi Mehta; Harsh Chalana; Harjot Singh; Richa Ghay Thaman
Journal:  Indian J Psychiatry       Date:  2020-12-12       Impact factor: 1.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.